• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Factors having greatest impact on performance in the next three years


State of the Industry survey results

"All of us in the industry are watching very carefully what's going on in Washington to determine the impact it's going to have not just on our organizations but on the industry in general," says Martin Hauser, president and CEO, SummaCare. "There's no doubt that change is going to come, but we're all going to have to remain flexible."

Administrative costs of insurance companies remain a political issue, but the irony is that plans already have a heavy administrative burden with existing regulations, according to Hauser. Like many organizations, SummaCare has a whole staff dedicated to compliance and regulatory review.

"There's a dollar amount attached to that, that somebody has to pay," he says.

As a result of the economic downturn, another influencing factor according to survey response, managed care overall has seen enrollment declines. The top 20 plans reported a 1% decline in the second quarter of 2009, while commercial PPO enrollment declined 5.3%. HMO/POS lives also declined 1.9%, according to Corporate Research Group.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.